Alliances
Wang, who has played a key role in the development of more than 25 innovative medicines at Eli Lilly and GlaxoSmithKline, made him the ideal fit for the company’s next chapter.
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
BMS inked a collaboration agreement with Exscientia that can leverage AI to speed the discovery of drug candidates in therapeutic areas, including oncology and immunology.
Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.
Eli Lilly announced a drug development collaboration with MiNA Therapeutics Limited focusing on five novel drug candidates that could be worth up to $245 million.
PRESS RELEASES